KR900017571A - 입상 항생제 제품의 제조방법 및 그 용도 - Google Patents

입상 항생제 제품의 제조방법 및 그 용도 Download PDF

Info

Publication number
KR900017571A
KR900017571A KR1019900006703A KR900006703A KR900017571A KR 900017571 A KR900017571 A KR 900017571A KR 1019900006703 A KR1019900006703 A KR 1019900006703A KR 900006703 A KR900006703 A KR 900006703A KR 900017571 A KR900017571 A KR 900017571A
Authority
KR
South Korea
Prior art keywords
layer
nucleus
polysaccharide
product
particle
Prior art date
Application number
KR1019900006703A
Other languages
English (en)
Other versions
KR0149997B1 (ko
Inventor
다니엘 싸맹
프레데릭 느규앙
미셀 데레
Original Assignee
미셀 데레
비오 세레 라모아뚜아르 에스 아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미셀 데레, 비오 세레 라모아뚜아르 에스 아 filed Critical 미셀 데레
Publication of KR900017571A publication Critical patent/KR900017571A/ko
Application granted granted Critical
Publication of KR0149997B1 publication Critical patent/KR0149997B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463—Organic compounds; Microorganisms; Enzymes
    • A23L3/3571—Microorganisms; Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

내용 없음

Description

입상 항생제 제품의 제조방법 및 그 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. 락토퍼옥시다제, 산소공여체 및 필요에 따라 산화성 물질로 구성되는 통칭 LP계 항생제계로부터 입상 항생제를 제조하되 산소 공여체가 과산화물이나 효소와 반응하는 물질 또는 미생물로 구성되고 LP계의 물리학적 성질을 변경시켜 수용액중에서 불용성인 입자를 형성하는 입상 항생제 제조방법에 있어서 LP계의 락토퍼옥시다제 효가가 친수성 다당류의 중합체로 구성된 핵을 내포하는 매개를 입자에 하이드록시 관능기 또는 유도체 관능기를 갖는 첫째층의 지질과 둘째층의 인지질을 통하여 핵에 화학적으로 결합되어 둘째층의 인지질과 첫째층의 지질에 침투되게 결합되고 물 이외의 용매중에서는 LP계 분자들이 매개물 입자내에 결합되지 않게 처리됨을 특징으로 하는 입상 항생제 제조방법.
  2. 청구범위 1항에서, 산소 공여체가 산화효소의 활성 물질을 포함하고 매개물 입자에는 산화 효소의 분자가 고정됨을 특징으로 하는 방법.
  3. 청구범위1항에서, 락토페틴LF에 의하여 보강되고 LF는 매개를 입자에 고정됨을 특징으로 하는 방법.
  4. 청구범위 1,2또는 3항에서, 입자가 슈퍼옥시디스쿠타제 SOD를 함유하고 이 SOD는 입자에 고정됨을 특징으로 하는 방법.
  5. 청구범위 1,2,3, 또는 4항에서, 첫째층을 형성할 때 첫째층의 지질에 이온 특성을 부여하기 위하여 첫째층의 지질을 구성함과 동시에 다당류의 핵 표면에 이온 특성을 부여하는 성분을 결합 시킴을 특징으로 하는방법.
  6. 청구범위 1항 내지 5항중 한 항에서, 입자가 전기적 전하를 띠도록 매개물 입자의 둘째층 인지질에 전기적 전하의 양측 친화성 분자를 첨가함을 특징으로 하는 방법.
  7. 청구범위 1항 내지 6항중의 한 항에서,매개물 입자에 결합시킬 성분(효소 및 필요에 따라 LF,SOD)를 결합시키는 방법이 아실기 핵을 형성하기 위하여 다당류의 비양자성 용매 없이 다당류 없이 다당류 핵에 지질층을 결합 시키고 생성된 아실기 핵을 둘째층의 인지질이나 인지질과 결합시킬 성분과 함께 인지질의 전이온도에 근접된 온도에서 수화시키는 공정으로 구성됨을 특징으로 하는 방법.
  8. 청구범위 5항과 7항에서, 다당류의 핵을 저농도의 무수 석신산중에서 지방산 염화물과 무수 카복실산의 혼합물에 반응시켜 다당류의 핵에 지방층과 이온성 작용기를 다당류의 핵에 결합 시킴을 특징으로 하는 방법.
  9. 청구범위 1항 내지 8항에서, 다가 알콜류 또는 콜로이드 물질 매개물을 입자 표면에 결합시킨후 당의를 피복함을 특징으로 하는 방법.
  10. 청구범위 1항 내지 9항에서, 핵이 아미돈, 덱스트란, 셀룰로우스와 같은 다당류 중합체로 제조됨을 특징으로 하는 방법.
  11. 청구범위 1항 내지 10항에서, 첫째층의 지질을 제4아민 촉매의 존해하에서 지방산 염화물 또는 무수지방산과 반을시켜 형성하여 디클롤로매탄중에서 다당류의 해과 동시에 분산 되도록함을 특징으로 하는 방법.
  12. 청구범위 11항에서, 지방산 염화물 또는 무수 지방산이 18 내지 22개의 탄소수 특히 18개의 탄소수를 갖는것임을 특징으로 하는 방법.
  13. 청구범위1항 내지 12항에서, 둘째층이 동물의 인지질이나 또는 킁의 레시틴, 계란의 레시틴 또는 우유의 레시틴과 같은 식품으로 부터 제조된 것임을 특징으로 하는 방법.
  14. 반응 물질인 효소와 필요에 따라 산화성 기질을 포함하고 락토퍼옥시다제 효소와 산소 공여체를 포함하는 입상 항생제 제품에 있어서 락토퍼옥시다제 효고가 친수성 단량체로 구성된 핵을 내포하는 매개물 입자에 결합되고 하이드록시 관능기 또는 유도체 관능기를 갖는 첫째층의 지질과 둘째층의 인지질을 통하여 화학적으로 결합되어 있어서 효소 분자가 둘째층의 인지질과 첫째층의 지질에 침투되어 있음을 특징으로 하는 입상 항생제 제품.
  15. 청구범위 14항에, 매개를 입자에 락토페린 LF와 슈퍼옥시디스무타제 SOD가 결합되어 있음을 특징으로 하는 제품.
  16. 청구범위 14항 또는15항에서, 첫째층의 내부가 이온화 특성을 갖고 있음을 특징으로 하는 제품.
  17. 청구범위 14항 내지 16항의 항생제 제품으로된 피부 치료용 점액이나 소화기관 치료용 의약제품으로 이용함을 특징으로 하는 항생제의 용도.
  18. 청구범위 14항 내지 16항의 항생제 제품으로된 감염 방지용 제품.
  19. 청구범위 14항 내지 16항의 항생제 제품을 포함하는 치약.
  20. ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019900006703A 1989-05-12 1990-05-11 입상 살균제 제품 및 그 제조방법 KR0149997B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR8906668 1989-05-12
FR8906668A FR2646777B1 (fr) 1989-05-12 1989-05-12 Procede de preparation d'un produit particulaire antimicrobien, produit antimicrobien obtenu et applications
FR89.06668 1989-05-12

Publications (2)

Publication Number Publication Date
KR900017571A true KR900017571A (ko) 1990-12-19
KR0149997B1 KR0149997B1 (ko) 1998-10-15

Family

ID=9381881

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900006703A KR0149997B1 (ko) 1989-05-12 1990-05-11 입상 살균제 제품 및 그 제조방법

Country Status (9)

Country Link
US (1) US5206156A (ko)
EP (1) EP0397227B1 (ko)
JP (1) JP3003045B2 (ko)
KR (1) KR0149997B1 (ko)
AT (1) ATE96680T1 (ko)
CA (1) CA2014847C (ko)
DE (1) DE69004329T2 (ko)
ES (1) ES2059990T3 (ko)
FR (1) FR2646777B1 (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9002422D0 (en) * 1990-02-03 1990-04-04 Boots Co Plc Anti-microbial compositions
WO1992014484A1 (en) * 1991-02-21 1992-09-03 Exoxemis, Inc. Methods and compositions for the treatment of infection and control of flora
US5389369A (en) * 1991-02-21 1995-02-14 Exoxemis, Inc. Halo peroxidase containing compositions for killing yeast and sporular microorganisms
US5756090A (en) * 1991-02-21 1998-05-26 Eoe, Inc. Oxygen activatable formulations for disinfection or sterilization
US5888505A (en) * 1991-02-21 1999-03-30 Eoe, Inc. Method for selectively inhibiting the growth of microbes using a haloperoxidase-halide-peroxide system
US5565197A (en) * 1991-02-21 1996-10-15 Exoxemis, Inc. Method which utilizes a haloperoxidase composition to inhibit the growth of microorganisms which cause sexually transmitted diseases
US5534501A (en) * 1991-06-04 1996-07-09 A Et S Biovecteurs Particle for use as a milk fat globule substitute, composition containing same and process for the preparation of said particle
US5736371A (en) * 1991-06-04 1998-04-07 A Et S Biovecteurs Biodegradable particulate vector for transporting molecules having biological activity
FR2677249B1 (fr) * 1991-06-04 1995-03-17 Biovecteurs As Vecteur particulaire biodegradable et procede de synthese.
FR2677272B1 (fr) * 1991-06-05 1995-03-03 Biovecteurs As Vecteur particulaire a tropisme selectif, procede de preparation et composition pharmaceutique.
NZ243106A (en) * 1991-06-11 1994-09-27 Gist Brocades Nv Composition capable of producing hydrogen peroxide (for at least 40 days) containing oxidoreductase and/or substrate in immobilised form and use for protecting food from microbes
US5747078A (en) * 1991-06-11 1998-05-05 Gist-Brocades, N.V. Longterm antimicrobial activity obtained by sustained release of hydrogen peroxide
GB9200891D0 (en) * 1992-01-16 1992-03-11 Mann Stephen P Formulation of microorganisms
US5656591A (en) * 1992-01-23 1997-08-12 Morinaga Milk Industry Co., Ltd. Antimicrobial agents and method for treating products therewith
FR2695034B1 (fr) 1992-09-01 1994-10-07 Oreal Composition cosmétique ou pharmaceutique comprenant en association une peroxydase et un agent anti-oxygène singulet.
JPH11505403A (ja) * 1994-07-14 1999-05-21 ノバルティス アクチエンゲゼルシャフト 微生物を含有する顆粒剤、およびそれらの製造方法および使用
ES2316154T3 (es) 1995-08-23 2009-04-01 University Of British Columbia Peptidos cationicos antimicrobianos y procedimientos de seleccion de los mismos.
SE506529C2 (sv) * 1996-01-23 1997-12-22 Semper Ab Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori
FR2750575B1 (fr) * 1996-07-04 1998-11-13 Labeyrie Sa Procede de decontamination de produits d'origine aquacole
JP2002544212A (ja) * 1999-05-14 2002-12-24 ユニバーシティ オブ オタゴ 耐微生物組成物
US6172040B1 (en) * 1999-05-28 2001-01-09 A. Satyanarayan Naidu Immobilized lactoferrin antimicrobial agents and the use thereof
FR2825373B1 (fr) 2001-05-31 2004-04-30 Tmi Europ Procede de production enzymatique d'un agent de traitement a l'etat fluide
US7125963B2 (en) * 2004-03-03 2006-10-24 En N Tech Inc Treatments for contaminant reduction in lactoferrin preparations and lactoferrin containing compositions
US7383859B2 (en) 2004-07-07 2008-06-10 Kabushiki Kaisha Toshiba Main steam valve for a steam turbine
US8945540B2 (en) * 2008-05-09 2015-02-03 Exoxemis, Inc. Compositions for enhancing the antibacterial activity of myeloperoxidase and methods of use thereof
CA2839747A1 (en) 2011-07-11 2013-01-17 Exoxemis, Inc. Eosinophil peroxidase compositions and methods of their use
CN105451573A (zh) * 2013-08-06 2016-03-30 比恩卡有限公司 抗微生物组合物以及其在食品保存中的用途
GB201417248D0 (en) * 2014-09-30 2014-11-12 Blueberry Therapeutics Ltd Compostion and methods of treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE23523E (en) * 1952-07-22 Enzymaticaiay deoxygenated
US2765233A (en) * 1953-05-29 1956-10-02 Sarett Enzyme-treated sheet product and article wrapped therewith
US3242051A (en) * 1958-12-22 1966-03-22 Ncr Co Coating by phase separation
US4233290A (en) * 1979-03-01 1980-11-11 Spa-Societa Prodotti Antibiotici, S.P.A. Method of treating domestic animals
US4486408A (en) * 1981-04-07 1984-12-04 Kiel Johnathan L Insoluble crosslinked cytotoxic oxidase-peroxidase system
LU85910A1 (fr) * 1985-05-22 1986-12-05 Oleofina Sa Procede pour eliminer l'oxygene dans les aliments et les boissons,et composition enzymatique utilisee a cet effet
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
FR2600250B1 (fr) * 1986-06-23 1989-11-24 Bio Serae Procede pour conditionner une composition antibacterienne et composition antibacterienne conditionnee
IT1197924B (it) * 1986-10-28 1988-12-21 Prodotti Antibiotici Spa Procedimento per la preparazione di alimenti di origine animale
SE8701839L (sv) * 1987-05-05 1988-11-06 Ewos Ab Livs- och fodermedel
JPS6447364A (en) * 1987-08-17 1989-02-21 Suntory Ltd Food and drink containing lactate monooxygenase
JPH0262829A (ja) * 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤
FR2631826B1 (fr) * 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation

Also Published As

Publication number Publication date
DE69004329T2 (de) 1994-05-19
US5206156A (en) 1993-04-27
FR2646777A1 (fr) 1990-11-16
EP0397227B1 (fr) 1993-11-03
JPH03193708A (ja) 1991-08-23
CA2014847A1 (fr) 1990-11-12
ES2059990T3 (es) 1994-11-16
CA2014847C (fr) 2000-06-13
DE69004329D1 (de) 1993-12-09
KR0149997B1 (ko) 1998-10-15
EP0397227A1 (fr) 1990-11-14
ATE96680T1 (de) 1993-11-15
JP3003045B2 (ja) 2000-01-24
FR2646777B1 (fr) 1993-09-03

Similar Documents

Publication Publication Date Title
KR900017571A (ko) 입상 항생제 제품의 제조방법 및 그 용도
Krunić et al. Application of whey protein and whey protein hydrolysate as protein based carrier for probiotic starter culture
JP2864033B2 (ja) 生物活性をもつ分子の輸送に特に有効な粒子キャリヤ（輸送担体）及びその調整方法
Mohammadi et al. Liposomal/nanoliposomal encapsulation of food-relevant enzymes and their application in the food industry
Chiou et al. Immobilization of Candida rugosa lipase on chitosan with activation of the hydroxyl groups
Beysseriat et al. Preliminary study of the influence of dietary fiber on the properties of oil-in-water emulsions passing through an in vitro human digestion model
Kitabatake et al. Digestibility of bovine milk whey protein and β-lactoglobulin in vitro and in vivo
US9040109B2 (en) Cross-linked biopolymers, related compositions and methods of use
Nakamura et al. Antioxidant activity of a maillard-type phosvitin− galactomannan conjugate with emulsifying properties and heat stability
JP4593697B2 (ja) リパーゼおよびプロテアーゼ含有消化酵素混合物の水溶性医薬製剤中の安定化添加物、該添加物を含有する製剤および消化酵素混合物を製造するためのキット
Sakai et al. Improved functional properties of meat analogs by laccase catalyzed protein and pectin crosslinks
Souza et al. Lactase (β-galactosidase) immobilization by complex formation: Impact of biopolymers on enzyme activity
A Chaudhari et al. Immobilization of proteins in alginate: functional properties and applications
Magnin et al. Immobilization of enzymes into a polyionic hydrogel: Chitoxan
Reyhani Poul et al. Physicochemical and antioxidant properties of chitosan-coated nanoliposome loaded with bioactive peptides produced from shrimp wastes hydrolysis
Chang et al. Rapid separation of lysozyme from chicken egg white by reductants and thermal treatment
Caseli et al. Chitosan as a removing agent of β-lactoglobulin from membrane models
Wang et al. Immobilization of interfacial activated Candida rugosa lipase onto magnetic chitosan using Dialdehyde cellulose as cross-linking agent
Huang et al. Effect of nanoliposomal entrapment on antioxidative hydrolysates from goose blood protein
Sunamoto et al. Polymer coated liposomes for drug delivery to target specific organs
de La Fournière et al. Surface behaviour of human pancreatic and gastric lipases
Zaitsev et al. Effect of some charged polymers on the activity of pancreatic porcine lipase
JP2000245492A (ja) 微生物抽出脂質
Torabizadeh et al. Inulin hydrolysis by immobilized inulinase on functionalized magnetic nanoparticles using soy protein isolate and bovine serum albumin
Kim et al. Optimal conditions for the encapsulation of Weissella cibaria JW15 using alginate and chicory root and evaluation of capsule stability in a simulated gastrointestinal system

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20010521

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee